Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tecentriq Atezolizumab Small Cell Lung Cancer (SCLC) Do not reimburse Complete
Tecentriq Atezolizumab Withdrawn
Tecentriq atezolizumab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Tecentriq atezolizumab Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Tecentriq & Avastin Atezolizumab & Bevacizumab NSQ-NSCLC Do not reimburse Complete
Tecentriq & Avastin Atezolizumab & Bevacizumab Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Complete
Tecfidera Dimethyl fumarate Multiple sclerosis, relapsing-remitting List with criteria/condition Complete
Technivie Ombitasvir/ paritaprevir/ ritonavir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Tecvayli teclistamab Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Tegsedi inotersen hereditary transthyretin amyloidosis Reimburse with clinical criteria and/or conditions Complete
Telzir Fosamprenavir calcium HIV infection List in a similar manner to other drugs in class Complete
Tepmetko tepotinib Locally advanced or metastatic non-small cell lung cancer Do not reimburse Complete
Teveten Plus Eprosartan mesylate/ hydrochlorothiazide Hypertension, Essential List in a similar manner to other drugs in class Complete
Tezspire tezepelumab Asthma Reimburse with clinical criteria and/or conditions Complete
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete
Tibsovo ivosidenib Acute myeloid leukemia (AML) Reimburse with clinical criteria and/or conditions Active
Tivicay Dolutegravir HIV infection List Complete
Toctino Alitretinoin Eczema List with clinical criteria and/or conditions Complete
Toviaz Fesoterodine fumarate Overactive bladder List in a similar manner Complete
Trajenta Linagliptin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete
Tramacet Tramadol hydrochloride /acetaminophen Acute pain Do not list Complete
Translarna ataluren Cancelled
Treanda Bendamustine hydrochloride Chronic Lymphocytic Leukemia (relapsed/refractory) Do not reimburse Complete
Treanda Bendamustine hydrochloride Chronic Lymphocytic Leukemia (first-line) Reimburse with clinical criteria and/or conditions Complete